Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Study

AbstractIntroductionEzetimibe/statin combination therapy has been reported to provide additional cardioprotective effects compared to statin monotherapy. The apolipoprotein B/A1 (apoB/A1) ratio is an effective predictor of cardiovascular diseases. The aim of this study was to compare the efficacy and safety of rosuvastatin/ezetimibe combination therapy versus rosuvastatin monotherapy using the apoB/A1 ratio in patients with diabetes and hypercholesterolemia.MethodsIn this randomized, multicenter, open-label, parallel-group study, patients were randomly assigned to receive the combination therapy of rosuvastatin 5  mg/ezetimibe 10 mg once daily (n = 68) or monotherapy with rosuvastatin 10 mg once daily (n = 68), for 8 weeks.ResultsAfter the 8-week treatment, percentage change (least-square means ± standard error) in the apoB/A1 ratio in the rosuvastatin/ezetimibe group was significantly decreased compared to the rosuvastatin group (− 46.14 ± 1.58% vs.  − 41.30 ± 1.58%, respectively;P = 0.03). In addition, the proportion of patients achieving> 50% reduction in low-density lipoprotein-cholesterol (LDL-C) and in the comprehensive lipid target (LDL-C  
Source: Diabetes Therapy - Category: Endocrinology Source Type: research

Related Links:

Authors: Hermans MP, Ahn SA, Rousseau MF Abstract Background: New recommendations call for lowering LDL-C 
Source: Acta Cardiologica - Category: Cardiology Tags: Acta Cardiol Source Type: research
Type 2 diabetes (T2D) is associated with increased risk of cardiovascular disease (CVD). In insulin resistant states such as the metabolic syndrome, overproduction and impaired clearance of liver-derived very-low-density lipoproteins and gut-derived chylomicrons (CMs) contribute to hypertriglyceridemia and elevated atherogenic remnant lipoproteins. Although ingested fat is the major stimulus of CM secretion, intestinal lipid handling and ultimately CM secretory rate is determined by numerous additional regulatory inputs including nutrients, hormones and neural signals that fine tune CM secretion during fasted and fed state...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
There is evidence of statin benefit among patients with diabetes regardless of cholesterol levels or prior cardiovascular disease history. Despite the evidence, there is under-prescription of statins in clinic...
Source: BMC Endocrine Disorders - Category: Endocrinology Authors: Tags: Research article Source Type: research
Sodium –glucose cotransporter-2 inhibitors (gliflozins) and statins are oral drugs that may have beneficial cardiovascular effects in patients with type 2 diabetes, especially in those with known cardiovascular disease. We planned a systematic review and meta-analysis of cardiovascular outcome trials (CV OTs) that evaluated the effect of gliflozins on MACE risk in patients with T2D stratified by age and by statin use.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research
Rural residence and ethnic-minority status are individually associated with increased cardiovascular (CV) mortality. Statin therapy is known to reduce the risk of CV mortality. While ethnic disparities in statin treatment exist, the joint impact of urban/rural residence and race/ethnicity on statin prescribing is unclear. Veterans Health Administration (VHA) and Centers for Medicare and Medicaid data were used to perform a longitudinal study of Veterans with Type 2 diabetes mellitus from 2007-2016.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
AbstractAtherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D). Not only is T2D a risk factor for ASCVD, common comorbid conditions, such as dyslipidaemia and hypertension, are also risk factors for ASCVD. Controlling these risk factors with agents with proven cardiovascular benefits (e.g. metformin, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 receptor inhibitors, statins, ACE inhibitors and angiotensin receptor blockers) provides considerable clinical benefits.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Abstract Diabetic dyslipidemia is a common condition in patients with Type 2 diabetes mellitus (T2DM). However, with the increasing application of statins which mainly decrease low-density lipoprotein cholesterol (LDL-C) levels, clinical trials and meta-analysis showed a clearly increase of the incidence of new-onset DMs, partly due to genetic factors. To determine whether a causal relationship exists between LDL-C and T2DM, we conducted a two-sample Mendelian Randomization (MR) analysis using genetic variations as instrumental variables (IVs). Initially, 29 SNPs significantly related to LDL-C (P≤ 5.0×10-...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
(Natural News) If you’ve ever suspected that certain medical treatments seem to be trading one problem for another, you may be onto something. Case in point: A recent study revealed that people who take statins in hopes of reducing their risk of cardiovascular events could be raising their risk of diabetes in the process. In...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
CONCLUSION: Pharmaceutical approach of CVD in T2DM is multilevel and complex. Drug classes featuring pleiotropic effects may boost our armamentarium in the fight against CVD. PMID: 32013815 [PubMed - in process]
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Vasc Pharmacol Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Crestor | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Rosuvastatin | Statin Therapy | Study | Vytorin | Zetia